Tempus AI Expands Bristol Myers Partnership With Multi-Year Oncology, AI Data Deals
By Adriano Marchese
Tempus AI signed a multi-year deal with Bristol Myers Squibb to license oncological data and provide access to its artificial intelligence-powered platform.
Under the terms of the deal, Bristol Myers will gain access to Tempus's Lens Platform, the company's agentic AI platform for oncology drug development, which is built on real-world multimodal datasets.
The agreement will run through 2031 to support biological and clinical insight, novel drug target discovery and therapeutic development across the pharmaceutical company's oncology portfolio.
Additionally, clinical-stage technology firm Pathos AI is also broadening its strategic collaborations with both Bristol Myers and Tempus AI. The collaboration aims to build a specialized, curated dataset and agentic AI capabilities for Alzheimer's disease and other neurological conditions.
Bristol Myers led a $237 million Series E financing round for Pathos at a $3 billion valuation, gaining rights to Pathos' Foundry AI platform and broader portfolio.
According to a regulatory filing on Friday, the combined agreements provide Tempus with $192.5 million in total cash commitments over five years, consisting of $137.5 million directly from Bristol Myers, and $55 million from Pathos AI for 500,000 de-identified patient records.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 23, 2026 10:31 ET (14:31 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy for the Long-Term While They’re Still Undervalued
6 ETFs To Diversify Away From AI
Why This Vanguard ETF Is One of the Best
The Best AI Stocks to Buy Now
United States